Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Abrocitinib in Pediatric Participants With Moderate-to-Severe Atopic Dermatitis
NCT06807281Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Primary completion
- Feb 2032
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Started Dec 2025; status: recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06807281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807281.